RediNews
ETFs Holding ACAD »    ACAD Historical Stock Prices »
ACAD News Video: Wed, May 10, 2017, 12:56 PM — Wednesday's ETF Movers: GDXJ, BBH


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acadia Pharmaceuticals is a biopharmaceutical company focused on development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders. Co.'s portfolio of products includes its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors. In addition to PD Psychosis, Co.'s pipeline includes multiple product opportunities being explored in clinical development across several CNS disorders. Self directed investors in Acadia Pharmaceuticals Inc will be interested in keeping up with all Acadia Pharmaceuticals Inc news they can find, both ACAD news originating from the company in the form of press releases, as well as seeing how independent media outlets are reporting news on ACAD. At RediNews, we simplify this task by presenting both ACAD news releases originating from Acadia Pharmaceuticals Inc itself, and ACAD news from a variety of media outlets. Visitors can browse this news online and through our ACAD RSS news feed.

ACAD News

ACAD News — Articles, Videos, & Press Releases

Implied FXH Analyst Target Price: $74
Thursday, October 19, 2017, 8:30 AM — ETF Channel
Valeant Reports Positive Results on Psoriasis Drug Siliq
Friday, October 13, 2017, 1:01 PM — Zacks
Lilly's Verzenio Gets Priority Review in First-Line Setting
Friday, October 13, 2017, 7:02 AM — Zacks
Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017
Thursday, October 12, 2017, 4:56 PM — Zacks
Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA
Wednesday, October 11, 2017, 1:34 PM — Zacks
Short Interest Plummets 60.7% For ACAD
Wednesday, October 11, 2017, 1:27 PM — Market News Video
Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel
Tuesday, October 10, 2017, 2:50 PM — Zacks
Why Should You Invest in Novo Nordisk (NVO) Stock Right Now
Tuesday, October 10, 2017, 7:34 AM — Zacks
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
Monday, October 9, 2017, 9:54 AM — Zacks
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
Monday, October 9, 2017, 7:25 AM — Zacks
Roche (RHHBY) Receives FDA Approval For Cobas Zika Test
Monday, October 9, 2017, 6:48 AM — Zacks
ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status
Thursday, October 5, 2017, 9:57 AM — Zacks
Ligand (LGND) Signs Deal to Acquire Crystal Bioscience
Thursday, October 5, 2017, 8:52 AM — Zacks
Celsion's Immunotherapy Candidate Impresses, Stock Surges
Wednesday, October 4, 2017, 10:24 AM — Zacks
Emergent Completes Acquisition of Anthrax Drug Raxibacumab
Wednesday, October 4, 2017, 10:11 AM — Zacks
Noteworthy Friday Option Activity: GRA, DDD, ACAD
Friday, September 29, 2017, 11:30 AM — Stock Options Channel
Allergan Authorizes New $2B Share Buyback Plan, Stock Up
Tuesday, September 26, 2017, 3:07 PM — Zacks
Commit To Buy Acadia Pharmaceuticals At $25, Earn 8.2% Using Options
Thursday, September 21, 2017, 12:20 PM — Stock Options Channel
Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III
Thursday, September 21, 2017, 7:44 AM — Zacks
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials
Tuesday, September 19, 2017, 1:12 PM — Zacks
Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
Tuesday, September 19, 2017, 1:05 PM — Zacks
BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA
Monday, September 18, 2017, 3:37 PM — Zacks
The Math Shows FBT Can Go To $140
Friday, September 15, 2017, 8:24 AM — ETF Channel
GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down
Thursday, September 14, 2017, 3:50 PM — Zacks
Alexion (ALXN) Reports Interim Results for Soliris Study
Thursday, September 14, 2017, 9:05 AM — Zacks
Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick
Wednesday, September 13, 2017, 9:29 AM — Zacks
Marinus Stock Surges on Successful Phase II Epilepsy Study
Tuesday, September 12, 2017, 9:42 AM — Zacks
Ultragenyx's Burosumab Positive in Phase II for XLH and TIO
Tuesday, September 12, 2017, 8:31 AM — Zacks
BioMarin Presents Interim Data on BMN 250 from Phase I/II
Thursday, September 7, 2017, 11:24 AM — Zacks
Merck (MRK) Opts for Buying German Immuno-Oncology Biotech
Thursday, September 7, 2017, 8:32 AM — Zacks
Notable ETF Inflow Detected - XBI, JUNO, EXEL, ACAD
Wednesday, September 6, 2017, 10:52 AM — ETF Channel
The Medicines Company's Infection Drug Vabomere Gets FDA Nod
Thursday, August 31, 2017, 7:26 AM — Zacks
FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
Wednesday, August 30, 2017, 9:06 AM — Zacks
The Medicines Co's Inclisiran Positive in Extension Study
Tuesday, August 29, 2017, 3:41 PM — Zacks
Anthera's Blisibimod Positive in Phase II Extension Study
Tuesday, August 29, 2017, 8:14 AM — Zacks
J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III
Monday, August 28, 2017, 5:12 PM — Zacks
Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval
Monday, August 28, 2017, 5:02 PM — Zacks
Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
Friday, August 25, 2017, 8:45 AM — Zacks
Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate
Friday, August 25, 2017, 8:23 AM — Zacks
Kite Pharma at New 52-Week High: What's Driving the Stock?
Thursday, August 24, 2017, 12:34 PM — Zacks
Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data
Wednesday, August 23, 2017, 2:06 PM — Zacks
Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer
Friday, August 18, 2017, 8:28 AM — Zacks
FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa
Thursday, August 17, 2017, 8:22 AM — Zacks
What You See, and What You Get: The Neurology of Perception
Tuesday, August 15, 2017, 4:28 PM — Zacks
Analysts Forecast 10% Gains Ahead For VXF
Monday, August 14, 2017, 8:44 AM — ETF Channel
Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern
Monday, August 14, 2017, 8:37 AM — Zacks
Barry Rosenstein Vs. The Shorts: Five Surprising Holdings
Thursday, August 10, 2017, 2:51 PM — Dividend Channel
Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More
Monday, August 7, 2017, 8:32 AM — Zacks
Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?
Wednesday, August 2, 2017, 6:49 AM — Zacks
Short Sellers Drawn To These Five Barry Rosenstein Holdings
Thursday, July 13, 2017, 1:58 PM — Dividend Channel
The Math Shows BBH Can Go To $140
Wednesday, July 12, 2017, 9:09 AM — ETF Channel
Barry Rosenstein Vs. The Shorts: Five Surprising Holdings
Tuesday, June 27, 2017, 2:10 PM — Dividend Channel
Minerva On Track to Initiate Phase III Schizophrenia Study
Monday, June 26, 2017, 7:35 AM — Zacks
Interesting ACAD Put And Call Options For August 18th
Tuesday, June 20, 2017, 11:02 AM — Stock Options Channel
Barry Rosenstein Vs. The Shorts: Five Surprising Holdings
Monday, June 12, 2017, 2:39 PM — Dividend Channel
Sum Up The Pieces: BBH Could Be Worth $138
Tuesday, June 6, 2017, 9:23 AM — ETF Channel
Barry Rosenstein Vs. The Shorts: Five Surprising Holdings
Thursday, May 25, 2017, 3:04 PM — Dividend Channel
Interesting ACAD Put And Call Options For July 21st
Tuesday, May 23, 2017, 10:39 AM — Stock Options Channel
5 Barry Rosenstein Holdings Attracting Short Sellers
Wednesday, May 10, 2017, 1:22 PM — Dividend Channel
Oversold Conditions For Acadia Pharmaceuticals (ACAD)
Wednesday, May 10, 2017, 12:04 PM — Dividend Channel
Noteworthy Wednesday Option Activity: SPA, ACAD, AAXN
Wednesday, May 10, 2017, 11:31 AM — Stock Options Channel
Acadia Pharmaceuticals Moves Up In Market Cap Rank, Passing Teradata
Friday, May 5, 2017, 4:35 PM — Market News Video
Analysts Forecast 12% Upside For BBH
Thursday, May 4, 2017, 8:49 AM — ETF Channel
5 Barry Rosenstein Holdings Attracting Short Sellers
Wednesday, April 26, 2017, 1:15 PM — Dividend Channel
5 Barry Rosenstein Holdings Attracting Short Sellers
Wednesday, April 12, 2017, 2:14 PM — Dividend Channel
ACAD Crosses Below Key Moving Average Level
Friday, April 7, 2017, 11:38 AM — Market News Video
Acadia Pharmaceuticals Becomes Oversold (ACAD)
Wednesday, April 5, 2017, 4:28 PM — Dividend Channel
Implied IYH Analyst Target Price: $171
Monday, April 3, 2017, 8:22 AM — ETF Channel
Barry Rosenstein Vs. The Shorts: Five Surprising Holdings
Monday, March 27, 2017, 1:40 PM — Dividend Channel
First Week of May 19th Options Trading For Acadia Pharmaceuticals (ACAD)
Wednesday, March 22, 2017, 11:42 AM — Stock Options Channel
Noteworthy ETF Outflows: XBI, CLVS, KITE, ACAD
Tuesday, March 21, 2017, 11:33 AM — ETF Channel
Barry Rosenstein Vs. The Shorts: Five Surprising Holdings
Friday, March 10, 2017, 1:23 PM — Dividend Channel
Analysts Expect BBH Will Reach $134
Thursday, March 2, 2017, 9:10 AM — ETF Channel
Noteworthy Wednesday Option Activity: RYN, VEEV, ACAD
Wednesday, March 1, 2017, 3:34 PM — Stock Options Channel
ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
Thursday, February 23, 2017, 3:16 PM — Zacks
First Week of April 21st Options Trading For Acadia Pharmaceuticals
Wednesday, February 22, 2017, 11:45 AM — Stock Options Channel
FBT, ACAD, ALNY, KITE: ETF Outflow Alert
Tuesday, February 21, 2017, 10:57 AM — ETF Channel
5 Barry Rosenstein Holdings Attracting Short Sellers
Friday, February 10, 2017, 1:39 PM — Dividend Channel
Notable ETF Inflow Detected - XBI, CLVS, ACAD, UTHR
Thursday, February 2, 2017, 10:46 AM — ETF Channel
Acadia Pharmaceuticals (ACAD) Shares Cross Above 200 DMA
Thursday, January 26, 2017, 11:44 AM — Market News Video
Surprising Analyst 12-Month Target For FBT
Thursday, January 19, 2017, 9:38 AM — ETF Channel
SPDR S&P Biotech ETF Experiences Big Outflow
Thursday, January 5, 2017, 10:51 AM — ETF Channel
First Week of ACAD February 17th Options Trading
Thursday, January 5, 2017, 10:40 AM — Stock Options Channel
Noteworthy Wednesday Option Activity: GNMX, CSAL, ACAD
Wednesday, January 4, 2017, 3:28 PM — Stock Options Channel
Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD
Wednesday, January 4, 2017, 11:54 AM — Market News Video
Short Sellers Drawn To These Five Barry Rosenstein Holdings
Wednesday, December 28, 2016, 2:22 PM — Dividend Channel
ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint
Wednesday, December 21, 2016, 9:07 AM — Zacks
Notable Tuesday Option Activity: LLNW, FRED, ACAD
Tuesday, December 20, 2016, 11:45 AM — Stock Options Channel
Analysts Expect VONG Will Reach $119
Thursday, December 15, 2016, 9:00 AM — ETF Channel
Notable Monday Option Activity: ZUMZ, LE, ACAD
Monday, December 12, 2016, 3:31 PM — Stock Options Channel
5 Barry Rosenstein Holdings Attracting Short Sellers
Monday, December 12, 2016, 2:02 PM — Dividend Channel
Noteworthy Monday Option Activity: TSLA, PXD, ACAD
Monday, December 5, 2016, 11:26 AM — Stock Options Channel
ACADIA Starts Phase II Schizophrenia Study on Pimavanserin
Wednesday, November 16, 2016, 8:16 AM — Zacks
ACAD Crosses Above Key Moving Average Level
Thursday, November 10, 2016, 1:45 PM — Market News Video
How The Parts Add Up: FNY Headed For $33
Thursday, November 10, 2016, 9:00 AM — ETF Channel
Investors Snag ACAD 15.2% Cheaper Than Its Secondary Stock Offering
Wednesday, November 9, 2016, 9:58 AM — Dividend Channel
Arena (ARNA) Q3 Earnings: Will the Stock Pull a Surprise?
Friday, November 4, 2016, 3:39 PM — Zacks
Will Kite Pharma (KITE) Stock Surprise Post Q3 Earnings?
Friday, November 4, 2016, 2:57 PM — Zacks
What to Expect from Repros (RPRX) This Earnings Season
Friday, November 4, 2016, 2:37 AM — Zacks
Puma Biotechnology (PBYI) Q3 Earnings: What's in Store?
Thursday, November 3, 2016, 4:24 PM — Zacks
ACADIA Pharma (ACAD): Will It Disappoint in Q3 Earnings?
Monday, October 31, 2016, 7:23 AM — Zacks
Acadia Pharmaceuticals Becomes Oversold
Thursday, October 27, 2016, 4:29 PM — Dividend Channel
First Week of June 2017 Options Trading For Acadia Pharmaceuticals (ACAD)
Tuesday, October 25, 2016, 10:39 AM — Stock Options Channel
Commit To Purchase Acadia Pharmaceuticals At $20, Earn 45.1% Annualized Using Options
Wednesday, October 19, 2016, 11:40 AM — Stock Options Channel
The Implied Analyst 12-Month Target For IWR
Monday, October 10, 2016, 9:23 AM — ETF Channel
Acadia Pharmaceuticals Enters Oversold Territory (ACAD)
Wednesday, October 5, 2016, 12:18 PM — Dividend Channel
Noteworthy Tuesday Option Activity: TITN, KRA, ACAD
Tuesday, October 4, 2016, 3:44 PM — Stock Options Channel
Notable Two Hundred Day Moving Average Cross - ACAD
Tuesday, October 4, 2016, 12:50 PM — Market News Video
Analysts See 19% Gains Ahead For FBT
Friday, September 9, 2016, 7:56 AM — ETF Channel
Investors Land ACAD 6.0% Cheaper Than Its Secondary Stock Offering
Thursday, August 11, 2016, 10:11 AM — Dividend Channel
Surprising Analyst 12-Month Target For FBT
Monday, August 8, 2016, 8:07 AM — ETF Channel
5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Wednesday, August 3, 2016, 7:36 AM — Zacks
ACADIA (ACAD) Q2 Earnings: What's in Store for the Stock?
Tuesday, August 2, 2016, 5:54 AM — Zacks
Acadia Pharmaceuticals Larger Than S&P 500 Component Discovery Communications
Monday, July 25, 2016, 4:38 PM — Market News Video
Commit To Buy Acadia Pharmaceuticals At $18, Earn 11.4% Using Options
Tuesday, July 19, 2016, 11:39 AM — Stock Options Channel
Analysts Forecast 12% Gains Ahead For IWF
Tuesday, July 5, 2016, 7:48 AM — ETF Channel
Noteworthy ETF Inflows: XBI, ACAD, ANAC, MDVN
Wednesday, June 15, 2016, 10:56 AM — ETF Channel
Noteworthy Monday Option Activity: EAT, ACAD, LNKD
Monday, June 6, 2016, 3:33 PM — Stock Options Channel
Notable ETF Inflow Detected - XBI, ACAD, ANAC, MDVN
Monday, June 6, 2016, 11:03 AM — ETF Channel
How The Parts Add Up: IYY Headed For $115
Tuesday, May 31, 2016, 7:58 AM — ETF Channel
XBI, ACAD, MDVN, ANAC: Large Inflows Detected at ETF
Thursday, May 26, 2016, 10:56 AM — ETF Channel
Bullish Two Hundred Day Moving Average Cross - ACAD
Tuesday, May 17, 2016, 11:32 AM — Market News Video
Notable ETF Outflow Detected - VTI, VIS, ACAD, CPHD
Wednesday, May 11, 2016, 10:58 AM — ETF Channel
Notable Monday Option Activity: ACAD, ECL, EXPD
Monday, May 2, 2016, 3:25 PM — Stock Options Channel
SPDR S&P Biotech ETF Experiences Big Outflow
Monday, May 2, 2016, 11:04 AM — ETF Channel
Surprising Analyst 12-Month Target For IYH
Wednesday, April 27, 2016, 7:37 AM — ETF Channel
VTI, VIS, ACAD, CPHD: Large Inflows Detected at ETF
Thursday, April 21, 2016, 11:18 AM — ETF Channel
First Week of December 16th Options Trading For Acadia Pharmaceuticals (ACAD)
Tuesday, April 19, 2016, 10:42 AM — Stock Options Channel
SPDR S&P Biotech ETF Experiences Big Inflow
Wednesday, April 13, 2016, 10:52 AM — ETF Channel
Investors Grab ACAD 47.8% Cheaper Than Its Secondary Stock Offering
Thursday, April 7, 2016, 11:20 AM — Dividend Channel
SPDR S&P Biotech ETF Experiences Big Outflow
Tuesday, April 5, 2016, 11:03 AM — ETF Channel
Why did Acadia Pharma (ACAD) Gained 17% on the Day?
Monday, March 28, 2016, 3:08 PM — Zacks
Notable Monday Option Activity: FB, ACAD, SGMS
Monday, March 28, 2016, 11:36 AM — Stock Options Channel
XBI, NVAX, ACAD, SGEN: ETF Inflow Alert
Monday, March 28, 2016, 11:10 AM — ETF Channel
First Week of ACAD May 20th Options Trading
Tuesday, March 22, 2016, 11:22 AM — Stock Options Channel
Notable Friday Option Activity: AIRM, ACAD, SYK
Friday, March 18, 2016, 3:28 PM — Stock Options Channel
Surprising Analyst 12-Month Target For IYH
Monday, March 7, 2016, 7:34 AM — ETF Channel
Acadia Pharmaceuticals Becomes Oversold (ACAD)
Friday, February 5, 2016, 4:31 PM — Dividend Channel
How The Pieces Add Up: IYH Targets $175
Thursday, February 4, 2016, 8:03 AM — ETF Channel
April 15th Options Now Available For Acadia Pharmaceuticals (ACAD)
Monday, January 25, 2016, 11:08 AM — Stock Options Channel
First Week of ACAD September 16th Options Trading
Friday, January 22, 2016, 11:29 AM — Stock Options Channel
Commit To Purchase Acadia Pharmaceuticals At $18, Earn 18% Annualized Using Options
Monday, January 11, 2016, 4:28 PM — Stock Options Channel
Investors Snag ACAD 52.5% Lower Than Its Secondary Stock Offering
Friday, January 8, 2016, 10:01 AM — Dividend Channel
Oversold Conditions For Acadia Pharmaceuticals (ACAD)
Wednesday, January 6, 2016, 4:31 PM — Dividend Channel
Interesting ACAD Put And Call Options For January 2018
Monday, November 16, 2015, 11:41 AM — Stock Options Channel
Noteworthy Monday Option Activity: LPLA, ACAD, ECOM
Monday, November 2, 2015, 3:22 PM — Stock Options Channel
5 Sell-Ranked Biotechs That Fell More Than 5% Today
Friday, September 25, 2015, 3:53 PM — Zacks
Will Epizyme (EPZM) Miss Estimates This Earnings Season? - Analyst Blog
Wednesday, February 25, 2015, 10:00 AM — Zacks
Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog
Wednesday, February 4, 2015, 8:58 AM — Zacks
ACAD is categorized under the Healthcare sector; below are links to news for some other companies in the same sector:

GTIV News
BGMD News
CRIS News
MEIP News
LGND News
ARQL News
CRTX News
STAA News
BABY News
MDXG News

RediNews invites those seeking web page financial content for any internet portal, especially any vertical portal specializing in the markets where there is a web page for business, web page for markets, web page finance, etc., to integrate our free web site content, our RSS news feeds. These RSS feeds are found throughout our website wherever news and custom stock content is found, by clicking the RSS icon for any news page (which will look like this): . This dynamic financial content is ideal for sites that already feature stock data content such as historical stock price information whether in the form of a historical stock price table or a web page chart image, to supplement the other custom stock market content displayed.

ACAD News | www.RediNews.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.